Ben‐Quan Shen - Concepedia

Author

Ben‐Quan Shen

Cytokinetics (United States)ORCID

Also Known As

B.Q. Shen, Ben-Quan Shen, Ben‐Quan Shen

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Cytokinetics (United States)Genentech Sunesis (United States)University of California, San Francisco

About

Ben‐Quan Shen is an author at Cytokinetics (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.7K
2	Pharmacology	10	10	659
3	Immunology	7	7	1.4K
4	Cell Biology	5	5	1.2K
5	Pathology	3	3	196

Ben‐Quan Shen

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Ben‐Quan Shen, Keyang Xu, Luna Liu, Nature Biotechnology ImmunoengineeringImmunologyBioconjugationAntibody EngineeringImmunotherapeutics	2012	977
Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway Ben‐Quan Shen, David Y. Lee, Thomas F. Zioncheck Journal of Biological Chemistry	1999	287
Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro Ben‐Quan Shen, David Y. Lee, Hans‐Peter Gerber, Journal of Biological Chemistry	1998	212
Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats C. Andrew Boswell, Eduardo E. Mundo, Crystal Zhang, Bioconjugate Chemistry NanotherapeuticsLocal PharmacologyImmunologyCellular PharmacologyPharmacotherapy	2011	200
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, Clinical Cancer Research	2014	199
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells Guangmin Li, Jun Guo, Ben‐Quan Shen, Molecular Cancer Therapeutics	2018	175
Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism Ben‐Quan Shen, Daniela Bumbaca, Ola M. Saad, Current Drug Metabolism OncologyTrastuzumab EmtansineClinical CatabolismOncogenic AgentCatabolic Fate	2012	135
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 Daniela Bumbaca, Anne Wong, Elizabeth A. Drake, mAbs Immunocytochemical TechniqueImmunologyTherapeutic AntibodyImmunotherapyCancer Biology	2011	109
Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering Thomas H. Pillow, Janet Tien, Kathryn Parsons-Reponte, Journal of Medicinal Chemistry	2014	106
Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy Rebecca L. Best, Nichole E. LaPointe, Olga Azarenko, Toxicology and Applied Pharmacology Tubulin BindingMedicineCytoskeletonMatrix BiologyPharmacology	2021	95

Page 1